First they showed a good concordance between #TMB determined by whole-exome approach and the #FoundationOne panel (https://t.co/iptshAJJKN) https://t.co/FQpXqkiCPe
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden.
Mentions
Extended reach
Total likes
Video views
Mentions per month
Jun 2020 – Sep 2023Where it's discussed
-
Facebook6 posts
-
News6 articles
-
X / Twitter5 posts
-
YouTube3 videos
-
Blogs3 articles
AI synopsis
What people are saying
The group discusses the concordance between different testing approaches and emphasizes the significance of these genomic profiling methods, using terms like 'good concordance' and referencing prior publications. The tone suggests that some users grapple with understanding specific implications, while others recognize the potential for enhancing cancer diagnosis and treatment personalization.
The discussions reflect a mixed level of agreement; some recognize the technical validity while others express confusion or limited understanding.
While there's some curiosity about the technical details, overall engagement is modest, with some posts showing interest based on specific data points.
Participants reference technical aspects like concordance between methods and prior studies, indicating they are engaging with the research details.
The discussions highlight the importance of the findings for understanding tumor mutational burden and guiding treatment, signifying moderate impact sentiments.
Abstract in brief
- This study analyzed 100,000 human cancer genomes to understand tumor mutational burden (TMB), a biomarker that predicts patients' response to certain immunotherapies, and found that targeted genomic profiling can accurately measure TMB comparable to whole exome sequencing.
- The research revealed that high TMB occurs across various cancer types, including rare ones, and tends to increase with age, with significant associations identified between TMB and specific genetic mutations, such as alterations in the PMS2 gene's promoter region.
- The findings suggest that a relatively small targeted genomic test focusing on 11 million base pairs can effectively identify patients with high TMB, which could help personalize immunotherapy treatments and improve cancer care.
Top posts
Most liked on X and BlueskyAlso a prior publication from @BostonGenomics and crew here: https://t.co/SqrGiN1DTS
この10万人解析のDiscussionに理由が載ってるかと思って読み直したけど、書いてそうで書いてない https://t.co/BVTp8pKvWp
0% of 50 SI-NETs and 1,7% of pancreatic NEC had >20mut/Mb. https://t.co/zSLC49yefp 3.6% of 193 NETs had TMB high https://t.co/MrM0tZWmEC What do I miss because I do not understand this @myesmo recommendation⁉️ @FAndreMD
All mentions
Tumor Mutational Burden in 100,000 Human Cancer Genomes Analyzed
Tumor Mutational Burden Analysis in 100,000 Human Cancer Genomes
This study analyzed 100,000 human cancer genomes to understand tumor mutational burden, a biomarker that predicts response to immunotherapy. Targeted genomic profiling effectively measures TMB, identifying patients for…
Cancer Genome Study Reveals Tumor Mutational Burden Insights
This study analyzed 100,000 human cancer genomes to understand tumor mutational burden, a biomarker predicting response to immunotherapy. It highlights that targeted genomic profiling can effectively measure TMB, aiding…
この10万人解析のDiscussionに理由が載ってるかと思って読み直したけど、書いてそうで書いてない https://t.co/BVTp8pKvWp
0% of 50 SI-NETs and 1,7% of pancreatic NEC had >20mut/Mb. https://t.co/zSLC49yefp 3.6% of 193 NETs had TMB high https://t.co/MrM0tZWmEC What do I miss because I do not understand this @myesmo recommendation⁉️ @FAndreMD
First they showed a good concordance between #TMB determined by whole-exome approach and the #FoundationOne panel (https://t.co/iptshAJJKN) https://t.co/FQpXqkiCPe
RT @xelamb: Also a prior publication from @BostonGenomics and crew here: https://t.co/SqrGiN1DTS
Also a prior publication from @BostonGenomics and crew here: https://t.co/SqrGiN1DTS